Arizona State Retirement System Buys 19,063 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Arizona State Retirement System grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 36.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,735 shares of the company’s stock after purchasing an additional 19,063 shares during the period. Arizona State Retirement System’s holdings in Recursion Pharmaceuticals were worth $485,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Decker Retirement Planning Inc. acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at about $26,000. Private Trust Co. NA bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $27,000. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after acquiring an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC grew its position in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after acquiring an additional 4,091 shares during the last quarter. Finally, KBC Group NV raised its position in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $6.35 on Friday. The company has a market cap of $2.55 billion, a PE ratio of -4.15 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $12.36. The company’s 50-day moving average is $7.54 and its two-hundred day moving average is $7.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same quarter in the prior year, the company earned ($0.42) earnings per share. The company’s quarterly revenue was down 57.8% on a year-over-year basis. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on RXRX. Leerink Partners lowered their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. KeyCorp dropped their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.